NY-AQARA
Aqara, a leading provider of smart home products, announced the launch of its new Motion Sensor P1, an updated model of the best-selling Aqara Motion Sensor. The sensor is a PIR motion and motion-light sensor that detects motion as well as the ambient light status in the room, and can be used for home security and automation. Built on the previous generation, the P1 model further extends the battery life to a record length of up to 5 years*, thanks to more power-efficient technologies and the improved batteries. The new sensor has been made available on Amazon in the US , Canada , Germany and France , as well as via selective Aqara retailers in North America, Europe, Asia and Oceania**. It is expected to hit Amazon UK in the following weeks.
Based on the Zigbee 3.0 protocol which allows faster response, higher reliability and better compatibility, the Motion Sensor P1 adds more flexibility for users including a configurable detection timeout and the adjustable sensitivity level. No longer fixed at a 60-second timeout like the predecessor, the P1 sensor allows users to set the detection timeout between 1 to 200 seconds on the Aqara Home app. It’s also possible to set the sensitivity level to high, medium or low, which refers to the distance from which the sensor will be triggered from, so that false alarms could be reduced. By default which is medium sensitivity, the sensor supports a field of view (FoV) of 170° for up to 2 meters and 150° for up to 7 meters.
The P1 motion sensor are compatible with major smart home ecosystems including HomeKit, Alexa, IFTTT and more. Moreover, the sensor will support Matter - the new connectivity standard for IoT devices - via an OTA update of Aqara hubs after the Matter rollout. The sensor itself also supports OTA updates, which means that new features and fixes now can be added after the release of the product.
Motion sensor has become increasingly popular among smart home users, as it is a natural part of the majority of smart home automations. The combination of an Aqara hub, a Motion Sensor P1 and controller devices like smart wall switches and roller shade drivers can automate many routine tasks, such as turning on the lights, opening the sun shades or controlling the TV. Moreover, with P1’s built-in light sensor, the lights could be controlled more precisely. For example, users could set to turn on the hallway lights only when it’s dark and motion is detected, so that energy consumption is reduced, and the lifespan of lights is increased.
To celebrate the launch, Aqara now offers a 10% discount for the new Motion Sensor P1 on its Amazon brand stores. North American customers will enjoy the offer with the promo code MOTIONUS in the US and Canada , while European customers will enjoy it using the promo code EUMOTIONPI in Germany and France . Both codes will be valid through April 29, 2022.
For more details of the Motion Sensor P1, please visit our website .
* Based on lab test, on the assumption of LED trigger indicator disabled and detection timeout of no less than 30 seconds.
** Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005020/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
